Our areas of expertise
Emerging Programs & Innovation
While our current clinical platform centers on bone marrow–derived MSCs, Citospin is actively expanding its research and development capabilities to support the next generation of advanced biological therapies.
MSC Platform Expansion
Ongoing initiatives aim to enhance process efficiency, scalability, and product consistency across multiple therapeutic indications. These efforts strengthen our ability to support evolving clinical strategies.
EVs Research & Development
Citospin is developing proprietary research programs focused on cell-derived extracellular vesicles technologies. These initiatives explore cell-free biological approaches designed to complement and extend the therapeutic potential of cell-based platforms.
These programs are currently in research and preclinical development stages and reflect our long-term commitment to innovation in advanced therapies.
Future Growth
Building on more than 15 years of regulated experience, Citospin continues to evaluate new manufacturing capabilities and advanced therapeutic modalities to meet the growing demand for complex biological products.